Cargando…
Utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the United States
BACKGROUND: The first follow-on drug (Basaglar) of the originator insulin glargine (Lantus), a long-acting insulin for treatment of type 1 and type 2 diabetes mellitus (T1DM, T2DM), was approved in 2015 in the United States. Information on the uptake, user characteristics, and outcomes of follow-on...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387990/ https://www.ncbi.nlm.nih.gov/pubmed/37404073 http://dx.doi.org/10.18553/jmcp.2023.29.7.842 |
_version_ | 1785082009266159616 |
---|---|
author | Rai, Ashish Nam, Young Hee Mendelsohn, Aaron B Marshall, James McDermott, Cara L Toh, Sengwee Lockhart, Catherine M |
author_facet | Rai, Ashish Nam, Young Hee Mendelsohn, Aaron B Marshall, James McDermott, Cara L Toh, Sengwee Lockhart, Catherine M |
author_sort | Rai, Ashish |
collection | PubMed |
description | BACKGROUND: The first follow-on drug (Basaglar) of the originator insulin glargine (Lantus), a long-acting insulin for treatment of type 1 and type 2 diabetes mellitus (T1DM, T2DM), was approved in 2015 in the United States. Information on the uptake, user characteristics, and outcomes of follow-on insulin remains sparse. OBJECTIVE: To describe the utilization, user characteristics, and health outcomes of the follow-on insulin glargine and insulin glargine originators in a large, distributed network of primarily commercially insured patients in the United States. METHODS: We used health care claims data in the US Food and Drug Administration’s Sentinel common data model format across 5 research partners in the Biologics & Biosimilars Collective Intelligence Consortium distributed research network. Sentinel analytic tools were used to identify adult users of insulin glargine between January 1, 2011, and February 28, 2021, and describe patient demographics, baseline clinical characteristics, and adverse health events among users of the originators and the follow-on drug, stratified by diabetes type. RESULTS: We identified 508,438 users of originator drugs and 63,199 users of the follow-on drug. The proportions of the follow-on drug users among total insulin glargine users were 9.1% (n = 7,070) for T1DM and 11.4% (n=56,129) for T2DM. Follow-on use rose from 8.2% in 2017 to 24.8% in 2020, accompanied by a steady decrease in the use of originator drugs. Demographics of the users of the originators and follow-on drug were similar among the T1DM and T2DM groups. Overall, follow-on users had poorer baseline health profile and higher proportions of episodes with adverse events in the follow-up. CONCLUSIONS: We found evidence of increased uptake of the follow-on drug relative to the originator products in the post-2016 period. The differences in the base-line clinical characteristics between users of the originator products and the follow-on drug and their relationship with health outcomes merit further research. |
format | Online Article Text |
id | pubmed-10387990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Academy of Managed Care Pharmacy |
record_format | MEDLINE/PubMed |
spelling | pubmed-103879902023-07-31 Utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the United States Rai, Ashish Nam, Young Hee Mendelsohn, Aaron B Marshall, James McDermott, Cara L Toh, Sengwee Lockhart, Catherine M J Manag Care Spec Pharm Research Brief BACKGROUND: The first follow-on drug (Basaglar) of the originator insulin glargine (Lantus), a long-acting insulin for treatment of type 1 and type 2 diabetes mellitus (T1DM, T2DM), was approved in 2015 in the United States. Information on the uptake, user characteristics, and outcomes of follow-on insulin remains sparse. OBJECTIVE: To describe the utilization, user characteristics, and health outcomes of the follow-on insulin glargine and insulin glargine originators in a large, distributed network of primarily commercially insured patients in the United States. METHODS: We used health care claims data in the US Food and Drug Administration’s Sentinel common data model format across 5 research partners in the Biologics & Biosimilars Collective Intelligence Consortium distributed research network. Sentinel analytic tools were used to identify adult users of insulin glargine between January 1, 2011, and February 28, 2021, and describe patient demographics, baseline clinical characteristics, and adverse health events among users of the originators and the follow-on drug, stratified by diabetes type. RESULTS: We identified 508,438 users of originator drugs and 63,199 users of the follow-on drug. The proportions of the follow-on drug users among total insulin glargine users were 9.1% (n = 7,070) for T1DM and 11.4% (n=56,129) for T2DM. Follow-on use rose from 8.2% in 2017 to 24.8% in 2020, accompanied by a steady decrease in the use of originator drugs. Demographics of the users of the originators and follow-on drug were similar among the T1DM and T2DM groups. Overall, follow-on users had poorer baseline health profile and higher proportions of episodes with adverse events in the follow-up. CONCLUSIONS: We found evidence of increased uptake of the follow-on drug relative to the originator products in the post-2016 period. The differences in the base-line clinical characteristics between users of the originator products and the follow-on drug and their relationship with health outcomes merit further research. Academy of Managed Care Pharmacy 2023-07 /pmc/articles/PMC10387990/ /pubmed/37404073 http://dx.doi.org/10.18553/jmcp.2023.29.7.842 Text en Copyright © 2023, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Brief Rai, Ashish Nam, Young Hee Mendelsohn, Aaron B Marshall, James McDermott, Cara L Toh, Sengwee Lockhart, Catherine M Utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the United States |
title | Utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the United States |
title_full | Utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the United States |
title_fullStr | Utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the United States |
title_full_unstemmed | Utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the United States |
title_short | Utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the United States |
title_sort | utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the united states |
topic | Research Brief |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387990/ https://www.ncbi.nlm.nih.gov/pubmed/37404073 http://dx.doi.org/10.18553/jmcp.2023.29.7.842 |
work_keys_str_mv | AT raiashish utilizationusercharacteristicsandadverseoutcomesofinsulinglargineoriginatorsandfollowondruginpatientswithdiabetesintheunitedstates AT namyounghee utilizationusercharacteristicsandadverseoutcomesofinsulinglargineoriginatorsandfollowondruginpatientswithdiabetesintheunitedstates AT mendelsohnaaronb utilizationusercharacteristicsandadverseoutcomesofinsulinglargineoriginatorsandfollowondruginpatientswithdiabetesintheunitedstates AT marshalljames utilizationusercharacteristicsandadverseoutcomesofinsulinglargineoriginatorsandfollowondruginpatientswithdiabetesintheunitedstates AT mcdermottcaral utilizationusercharacteristicsandadverseoutcomesofinsulinglargineoriginatorsandfollowondruginpatientswithdiabetesintheunitedstates AT tohsengwee utilizationusercharacteristicsandadverseoutcomesofinsulinglargineoriginatorsandfollowondruginpatientswithdiabetesintheunitedstates AT lockhartcatherinem utilizationusercharacteristicsandadverseoutcomesofinsulinglargineoriginatorsandfollowondruginpatientswithdiabetesintheunitedstates |